Fig. 3: Prognostic implications and clinicopathological characteristics of patients stratified based on varying levels of CXCL7 expression. | Cell Death & Disease

Fig. 3: Prognostic implications and clinicopathological characteristics of patients stratified based on varying levels of CXCL7 expression.

From: Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway

Fig. 3

A The optimal cut-off value of the relative expression level of CXCL7. B The scatter plot illustrates the distribution of patient groups in relation to the gene expression levels of CXCL7. C Probability of pathological fracture in patients with different CXCL7 expression levels. D Probability of extramedullary invasion in patients with different CXCL7 expression levels. E Survival curves for overall survival time of patients in different CXCL7 groups. F Survival curves for progression-free-survival time of patients in different CXCL7 groups. G Correlation between the relative expression level of CXCL7 and the number of osteolytic bone lesions detected by PET-CT in 108 patients. H Survival curves for overall survival time of patients in different CXCL7 groups in the MMRF database).

Back to article page